Literature DB >> 28688656

Notch signaling promotes ductular reactions in biliary atresia.

Jessica A Zagory1, William Dietz1, Alex Park1, Michael Fenlon1, Jiabo Xu1, Sarah Utley1, Nirmala Mavila2, Kasper S Wang3.   

Abstract

BACKGROUND: Biliary atresia (BA) is a congenital, progressive, fibro-obliterative disease of the extrahepatic biliary tree and the most common cause of end-stage liver disease in children. BA is characterized by extensive intrahepatic proliferating ductular reactions that may contribute to biliary fibrosis. Lineage tracing during experimental cholestasis indicates that cells within ductular reactions derive from PROM1-expressing hepatic progenitor cells. Given the role of Notch signaling in normal biliary development, we hypothesize that activated Notch signaling promotes the formation of ductular reactions in BA.
METHODS: Liver samples collected from BA infants at Kasai portoenterostomy and age-matched controls, as well as from wild-type and Prom1 knockout mice with 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-induced experimental cholestasis were analyzed histologically using immunofluorescence and by quantitative polymerase chain reaction.
RESULTS: Increased expression of genes encoding Notch ligand JAG1 and its receptor NOTCH2 was observed in BA livers compared with control by quantitative polymerase chain reaction analyses. Livers of DDC-treated mice, which exhibit cytokeratin-19-positive ductular reactions typical of BA livers, demonstrated significant increases in the expression level of the gene encoding Notch2, as well as downstream Notch target gene Hes1 compared with control. Prom1 knockout mice exhibit diminished ductular reactions and decreased levels of Jag1 and Hes1 compared with littermate controls.
CONCLUSIONS: Human BA and cholestasis induced by DDC are associated with Notch signaling activation. Null mutation of Prom1 is associated with decreased ductular reactions and decreased Notch signaling activation during DDC treatment. These data are consistent with Notch signaling promoting ductular reactions of Prom1 expressing progenitor cells in BA.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biliary atresia; Ductular reaction; Fibrosis; Notch; Progenitor; Prominin-1

Mesh:

Substances:

Year:  2017        PMID: 28688656     DOI: 10.1016/j.jss.2017.03.051

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

Review 1.  Biliary Atresia: A Complex Hepatobiliary Disease with Variable Gene Involvement, Diagnostic Procedures, and Prognosis.

Authors:  Consolato M Sergi; Susan Gilmour
Journal:  Diagnostics (Basel)       Date:  2022-01-27

2.  The Role of GLI in the Regulation of Hepatic Epithelial-Mesenchymal Transition in Biliary Atresia.

Authors:  Pu Siyu; Wang Junxiang; Wang Qi; Zhang Yimao; Jin Shuguang
Journal:  Front Pediatr       Date:  2022-05-26       Impact factor: 3.569

3.  YAP Activation Drives Liver Regeneration after Cholestatic Damage Induced by Rbpj Deletion.

Authors:  Umesh Tharehalli; Michael Svinarenko; Johann M Kraus; Silke D Kühlwein; Robin Szekely; Ute Kiesle; Annika Scheffold; Thomas F E Barth; Alexander Kleger; Reinhold Schirmbeck; Hans A Kestler; Thomas Seufferlein; Franz Oswald; Sarah-Fee Katz; André Lechel
Journal:  Int J Mol Sci       Date:  2018-11-29       Impact factor: 5.923

4.  Cystic biliary atresia with paucity of bile ducts and gene mutation in KDM6A: a case report.

Authors:  Daisuke Masui; Suguru Fukahori; Tatsuki Mizuochi; Yoriko Watanabe; Kaori Fukui; Shinji Ishii; Nobuyuki Saikusa; Naoki Hashizume; Naruki Higashidate; Saki Sakamoto; Aiko Takato; Koh-Ichiro Yoshiura; Yoshiaki Tanaka; Minoru Yagi
Journal:  Surg Case Rep       Date:  2019-08-14

5.  Biliverdin reductase B impairs cholangiocarcinoma cell motility by inhibiting the Notch/Snail signaling pathway.

Authors:  Zhihui Gao; Xiaojian Ni; Bohao Zheng; Wentao Sun; Wenze Wan; Han Liu; Xiaoling Ni; Tao Suo; Na Li; Houbao Liu; Sheng Shen
Journal:  J Cancer       Date:  2022-04-04       Impact factor: 4.478

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.